The spectrum of CAEs includes both class-specific toxicities, such as HFSR in VEGFR inhibitors, and broader cutaneous manifestations like xerosis, eczematous dermatitis, pruritus, nail disorders, and pigmentary changes. This evidence concerns the gene KDR and Abnormality of skin pigmentation.